Cite
Adamson C, Jhund PS, Docherty KF, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021;23(10):1662-1672doi: 10.1002/ejhf.2308.
Adamson, C., Jhund, P. S., Docherty, K. F., Bělohlávek, J., Chiang, C. E., Diez, M., Drożdż, J., Dukát, A., Howlett, J., Ljungman, C. E. A., Petrie, M. C., Schou, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., Bengtsson, O., Langkilde, A. M., Lindholm, D., Sjöstrand, M., & McMurray, J. J. V. (2021). Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European journal of heart failure, 23(10), 1662-1672. https://doi.org/10.1002/ejhf.2308
Adamson, Carly, et al. "Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index." European journal of heart failure vol. 23,10 (2021): 1662-1672. doi: https://doi.org/10.1002/ejhf.2308
Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang CE, Diez M, Drożdż J, Dukát A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJV. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021 Oct;23(10):1662-1672. doi: 10.1002/ejhf.2308. Epub 2021 Jul 29. PMID: 34272791.
Copy
Download .nbib